Literature DB >> 19295460

Kaposi's sarcoma in the pediatric population: the critical need for a tissue diagnosis.

Lisa M Arkin1, Carrie M Cox, Carrie L Kovarik.   

Abstract

Kaposi's sarcoma (KS) is a low-grade vascular neoplasm mediated by the human herpesvirus-8. Only 1 clinical subtype, the endemic/African subtype, commonly affects the pediatric population. Although adults with KS often present with cutaneous findings and generalized lymphadenopathy, African children are more likely to present without classic skin findings. Definitive diagnosis requires histologic examination from tissue biopsy; however, as pathology resources are scarce in many developing African countries where KS is prominent, appropriate diagnosis and treatment of the condition are challenging. We report the case of a Malawian child who presented with generalized lymphadenopathy and was presumptively treated for lymphoma, with clinical worsening of his lesions. A diagnosis of KS was made after excisional biopsy of a superficial lymph node, with the initiation of appropriate therapy. The literature regarding pediatric KS is reviewed and recommendations are offered to allow accurate and timely diagnosis of the condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295460     DOI: 10.1097/INF.0b013e318193ee21

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.

Authors:  Soren Gantt; Abel Kakuru; Anna Wald; Victoria Walusansa; Lawrence Corey; Corey Casper; Jackson Orem
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

2.  High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population.

Authors:  Cornelia Feiterna-Sperling; Christoph Königs; Gundula Notheis; Bernd Buchholz; Renate Krüger; Katharina Weizsäcker; Josef Eberle; Nikola Hanhoff; Barbara Gärtner; Harald Heider; Detlev H Krüger; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2016-05-30       Impact factor: 3.402

Review 3.  A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population.

Authors:  Dorothy E Dow; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-09-04       Impact factor: 3.164

4.  The role of dermatopathology in conjunction with teledermatology in resource-limited settings: lessons from the African Teledermatology Project.

Authors:  Matthew W Tsang; Carrie L Kovarik
Journal:  Int J Dermatol       Date:  2011-02       Impact factor: 2.736

5.  Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study.

Authors:  Nader Kim El-Mallawany; William Kamiyango; Jeremy S Slone; Jimmy Villiera; Carrie L Kovarik; Carrie M Cox; Dirk P Dittmer; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

Review 6.  Rapidly progressive Kaposi's Sarcoma in an Iraqi boy received Valproic acid: a case report and review of literature.

Authors:  Lika'a Fasih Y Al-Kzayer; Peter Keizer; Farah T Abdulraheem; Kenji Sano; Minoru Kamata; Kazuo Sakashita; Laith A Y Habbaba; Kenichi Koike
Journal:  BMC Pediatr       Date:  2016-07-26       Impact factor: 2.125

7.  Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease.

Authors:  Nader Kim El-Mallawany; Jimmy Villiera; William Kamiyango; Erin C Peckham-Gregory; Michael E Scheurer; Carl E Allen; Casey L McAtee; Alejandra Legarreta; Dirk P Dittmer; Carrie L Kovarik; Elizabeth Y Chiao; Stephen C Martin; Nmazuo W Ozuah; Parth S Mehta; Peter N Kazembe
Journal:  Infect Agent Cancer       Date:  2018-11-09       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.